🇺🇸 FDA
Pipeline program

AK104

LungMate-027

Phase 2 small_molecule active

Quick answer

AK104 for Resectable Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Resectable Non-small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials